Niagen Bioscience (NAGE) Total Current Liabilities (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Total Current Liabilities of $22.8 million for Q1 2026, up 9.54% year-over-year from $20.8 million in Q1 2025, and up 14.58% quarter-over-quarter from $19.9 million in Q4 2025.
Niagen Bioscience (NAGE) Total Current Liabilities (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Total Current Liabilities for 14 consecutive years, with $22.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 9.54% year-over-year to $22.8 million; the TTM figure through Mar 2026 stood at $22.8 million (up 9.54% YoY), while the FY2025 annual figure was $19.9 million, up 10.98% from the prior year.
- Total Current Liabilities rose to $22.8 million in Q1 2026 per NAGE's latest filing, from $19.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $22.8 million in Q1 2026 and bottomed at $16.7 million in Q3 2022.
- Historically, Total Current Liabilities has averaged $19.4 million across 5 years, with a median of $19.1 million in 2023.
- Annual changes were most pronounced in 2024 — Total Current Liabilities decreased 12.97% — and 2025, when it climbed 28.32%.
- Niagen Bioscience's Total Current Liabilities stood at $17.9 million in 2022, then increased by 15.41% to $20.6 million in 2023, then slipped by 12.97% to $17.9 million in 2024, then grew by 10.98% to $19.9 million in 2025, then grew by 14.58% to $22.8 million in 2026.
- Business Quant data shows NAGE's Total Current Liabilities at $22.8 million in Q1 2026, $19.9 million in Q4 2025, and $22.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | 15.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.05 Mn |
| Mar 31, 2026 | 22.82 Mn |
| Dec 31, 2025 | 19.92 Mn |
| Sep 30, 2025 | 22.71 Mn |
| Jun 30, 2025 | 22.33 Mn |
| Mar 31, 2025 | 20.84 Mn |
| Dec 31, 2024 | 17.95 Mn |
| Sep 30, 2024 | 17.70 Mn |
| Jun 30, 2024 | 17.87 Mn |
| Mar 31, 2024 | 19.45 Mn |
| Dec 31, 2023 | 20.62 Mn |
| Sep 30, 2023 | 19.44 Mn |
| Jun 30, 2023 | 19.06 Mn |
| Mar 31, 2023 | 18.42 Mn |
| Dec 31, 2022 | 17.87 Mn |
| Sep 30, 2022 | 16.73 Mn |
| Jun 30, 2022 | 17.73 Mn |
| Mar 31, 2022 | 18.69 Mn |
| Dec 31, 2021 | 17.61 Mn |
| Sep 30, 2021 | 17.77 Mn |